During the past decade, Nagoya University Hospital conducted 123 clinical trials. In the 10-year time frame, 123 clinical trials started and 43 clinical trials were completed, i.e. on average, 35% percent of trials that started reached the finish line to date. In the past 5 years, 64 clinical trials started and 32 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nagoya University Hospital" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Pfizer" with 15 trials sponsored, "Amgen" with 7 trials sponsored, "Janssen Research & Development, LLC" with 6 trials sponsored and "Nagoya University" with 6 trials sponsored. Other sponsors include 84 different institutions and companies that sponsored additional 62 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nagoya University Hospital" #1 collaborator was "Chugai Pharmaceutical" with 6 trials as a collaborator, "Japan Agency for Medical Research and Development" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator and "Nagoya University" with 3 trials as a collaborator. Other collaborators include 66 different institutions and companies that were collaborators in the rest 62 trials.

According to Clinical.Site data, the most researched conditions in "Nagoya University Hospital" are "Hemophilia A" (6 trials), "Rheumatoid Arthritis" (5 trials), "ALS" (4 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials) and "Idiopathic Pulmonary Fibrosis" (4 trials). Many other conditions were trialed in "Nagoya University Hospital" in a lesser frequency.

Most popular intervention types in "Nagoya University Hospital" are "Drug" (112 trials), "Biological" (21 trials), "Other" (17 trials), "Device" (6 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "Sham Procedure" (7 trials), "Atezolizumab" (6 trials), "Faricimab" (6 trials) and "Aflibercept" (5 trials). Other intervention names were less common.

The vast majority of trials in "Nagoya University Hospital" are 133 trials for "All" genders, 10 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Nagoya University Hospital". undefined are not yet recruiting, 32 are recruiting, 41 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 60 completed trials in Nagoya University Hospital, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Nagoya University Hospital, 9 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 88 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".

Nagoya University Hospital has several departments that took part in Clinical trials: "Nagoya University Hospital - Transfusion Medicine" - 4 trials, "Department of Hematology, Nagoya University Graduate School of Medicine" - 3 trials, "Nagoya University Hospital; Urology" - 3 trials, "Department of Cardiology, Nagoya University Graduate School of Medicine" - 2 trials, "Nagoya City University Hospital - Dermatology" - 2 trials, "Nagoya University Hospital; Respiratory Medicine" - 2 trials